A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

This study has been completed.

Sponsor:

Collaborator:

Janssen-Cilag International NV

Information provided by:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

ClinicalTrials.gov Identifier:

NCT00111189

First received: May 17, 2005

Last updated: June 2, 2011

Last verified: June 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	February 2008
Primary Completion Date:	February 2007 (Final data collection date for primary outcome measure)